Essity AB ESSITY B
This picture changes. Follow Essity AB free — email when the signal or risk changes + a Sunday weekly brief.
Follow Essity AB freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Full analysis: 5 Apr 2026
Latest news check: 17 Jul 2026
General analysis — not personal advice.
NEUTRAL
7/10
Confidence
Keep the core position but reassess the case: monitor Cevian’s agenda/communications and management’s response, plus evidence that price/mix stabilises. Consider adding only if strategic steps become concrete or price/mix turns; reduce if margin pressure worsens without credible countermeasures.
Move from HOLD to REVIEW: Cevian’s >5% stake is a new, potentially high-impact catalyst that can change the investment case (structure/capital allocation). At the same time, Q2 still shows price/mix pressure and limited organic growth, so risk/reward should be reassessed before adding or reducing.
Market sentiment
8/10
↑
Trend: Improving
Sentiment has improved to clearly positive due to Cevian becoming a >5% shareholder and expectations of strategic actions, although Q2’s weak organic growth and negative price/mix temper enthusiasm.
Risk assessment
4/10
Dilution:
Low
Strong cash flow and buybacks; no issuance.
Jurisdiction:
Low
Mainly Sweden/EU and North America.
Execution:
Medium
Integration and cost-out must be delivered.
Recent changes
- Q2 delivered revenue of 35,061 MSEK and organic growth of 0.3% (volume +1.4%, price/mix -1.1%). Adjusted EBITA was 4,685 MSEK with a 13.4% margin.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (5) — follow the company freeAbout the company
Essity AB is a global producer of hygiene and health products with strong brands such as TENA and Tork. The company is mature and cash-flow generative, focusing on margin improvement through efficiency programs, buybacks, and selective acquisitions.
Sector:
Hygiene and health products
Type:
Other
Next report
22 Oct 2026
Q3
Catalysts
1 Jan 2027
Falkenberg central logistics hub (go-live)
Medium
Q4 2026
UK recycled paper plant opening
Medium
Unknown
Strategic review of Consumer Tissue (6–12 months)
High
Horizon:
Bull case
Q1 earnings could confirm continued margin strength
- Share buybacks provide technical support and EPS uplift
- Early positive read-through from Edgewell integration
Bear case
Weak volumes and pricing pressure in tissue
- Input/energy costs could turn volatile
- Macro pressure may drive downtrading to private label
Signal rationale (informational)
Move from HOLD to REVIEW: Cevian’s >5% stake is a new, potentially high-impact catalyst that can change the investment case (structure/capital allocation). At the same time, Q2 still shows price/mix pressure and limited organic growth, so risk/reward should be reassessed before adding or reducing.
Recent news
- Since 2026-06-19, Essity has continued its SEK 3bn buyback program with weekly repurchases. On 16 July it released Q2 2026: net sales SEK 35,061m, organic growth 0.3% (volume +1.4%, price/mix -1.1%), adjusted EBITA SEK 4,685m and adjusted EBITA margin 13.4%. The share fell ~2.6–3.0% on the report day. Cevian Capital subsequently disclosed a stake above 5% in Essity, increasing the likelihood of strategic actions (e.g., portfolio/structural moves).
Price & valuation
Last close
SEK 278
1 week
-1.7 %
3 months
+12.6 %
12 months
+18.2 %
From 52w high
-1.7 %
From 52w low
+20.2 %
Exchange
Stockholm
Sector
Hygiene and health products
This picture changes. Follow Essity AB free — email when the signal or risk changes + a Sunday weekly brief.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.